Real-World Effectiveness and Safety of Treatment With Tildrakizumab Over 64 Weeks in Patients With Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis
J Drugs Dermatol 2022 Aug 01;23(8)612-618, J Heim, JG Vasquez, T Bhutani, J Koo, J Mathew, R Gogineni, T Ferro, N BhatiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.